Skip Navigation
Search Menu
Find an Expert

 


Thomas W Donner, M.D.

Photo of Dr. Thomas W Donner, M.D.

Director, Johns Hopkins Diabetes Center

Associate Professor of Medicine

Male

Expertise: Diabetes and Cardiovascular Diseases, Endocrinology

Research Interests: Type 1 Diabetes; Insulin Therapy; Immunotherapy

Request an Appointment

I live in Maryland

410-955-9270
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

The Johns Hopkins Hospital
Appointment Phone: 410-955-9270

600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map
Phone: 410-955-2908
Fax: 410-614-9586

Johns Hopkins Outpatient Center
Appointment Phone: 410-955-9270

601 N. Caroline St.
Baltimore, MD 21287 map
Phone: 410-955-2908
Fax: 410-614-9586

Contact for Research Inquiries

Baltimore, MD 21205 map
Phone: 443-287-7843

Email me

Background

Dr. Donner's clinical and research interests have focused on the prevention of complications in patients with type 1 and 2 diabetes. For 6 years, he was the Associate Medical Director of the Joslin Diabetes Center affiliate at the University of Maryland, and then Medical Director from 2004 - 2010. After joining the faculty at Johns Hopkins University in 2010, his clinical and research interests became fully dedicated to diabetes. He became the Director of The Johns Hopkins Diabetes Center in 2011. He has been a clinical investigator in a number of NIH- and industry-funded diabetes research trials. Dr. Donner was a co-PI in the NIH-funded Veterans Affairs Implantable Insulin Pump Study, a Co-PI on the NIDDK-funded Diabetes Control and Complications Trial / Epidemiology of Diabetes Intervention and Complications (DCCT / EDIC) Study for 16 years, and Co-PI for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) for 7 years. Recently, he has served as PI for the Durable-response therapy Evaluation For Early or New-onset type 1 Diabetes (DEFEND-1). Dr. Donner is currently collaborating with Dr. Abdel Hamad in Immunology on preventing B-regulatory cell apoptosis using a novel monoclonal antibody targeting the presumptive apoptotic factor. This antibody prevents the development of type 1 diabetes in non obese diabetic mice. Dr. Donner is the PI for Johns Hopkins for TrialNet, a multicenter, international consortium of investigators studying ways to prevent Type 1 diabetes and preserve insulin secretion in individuals with newly diagnosed Type 1 diabetes. He is also a PI for a study investigating FIAsp, a faster-acting insulin aspart in subjects with type 1 diabetes, and is working with investigators at the Johns Hopkins School of Engineering on an implantable insulin pump which delivers insulin intravenously.

...read more

Titles

  • Director, Johns Hopkins Diabetes Center
  • Associate Professor of Medicine

Education

Degrees

  • MD, University of Virginia School of Medicine (1986)

Residencies

  • University of Maryland Medical Center / Internal Medicine (1989)
  • University of Maryland Medical Center / Internal Medicine (1994)

Fellowships

  • University of Maryland Medical Center / Endocrinology (1993)

Board Certifications

  • American Board of Internal Medicine / Endocrinology (1991, 2007)
  • American Board of Internal Medicine / Internal Medicine (1989)

Research & Publications

Research Summary

Dr. Donner's clinical and research interests include aggressive management of type 1 and type 2 diabetes, preserving beta cell function in patients with new onset type 1 diabetes, and the prevention of diabetes complications.

Clinical Trials

1. 1R01AI099027-01 NIH/NIAID  Hamad (PI) 03/01/13 - 03/31/18                                                                                                                                       

Mechanisms of Fas Ligand control of insulitis initiation in autoimmune diabetes

Role: Co-investigator

2. NIDDK   Donner (PI) 05/13 – present

The Natural History Study of the Development of Type 1 Diabetes

Role: PI

3. NovoNordisk     Donner (PI)     10/13 - present

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

 

Activities & Honors

Memberships

  • American Diabetes Association
  • Endocrine Society
Is this you? Edit Profile